(GRDN) Guardian Pharmacy Services - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NYSE (USA) | Market Cap: 2.437m USD | Total Return: 74.4% in 12m
Avg Turnover: 12.8M
Qual. Beats: 0
Rev. Trend: 99.7%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Idiosyncratic Leader
Guardian Pharmacy Services (NYSE: GRDN) provides specialized pharmacy solutions tailored for residents in lower-acuity long-term care facilities (LTCFs), including assisted living and behavioral health environments. The company utilizes its proprietary Guardian Compass technology suite to automate medication dispensing, conduct quality assurance on prescriptions, and provide data analytics for resident drug spending. This decentralized business model allows local pharmacies to optimize operations while maintaining clinical compliance across diverse regulatory landscapes.
The long-term care pharmacy sector is characterized by high barriers to entry due to complex multi-state licensing requirements and the necessity for specialized packaging that integrates with facility electronic health records. Unlike standard retail pharmacies, LTC providers focus on high-touch services such as medication synchronization and 24/7 delivery to manage the chronic health needs of aging populations. For a deeper analysis of these industry tailwinds and valuation metrics, consider exploring the data available on ValueRay.
Founded in 2003 and based in Atlanta, Georgia, the company operates within the Drug Retail GICS sub-industry. Its service offering is built around a rules-engine technology designed to reduce administrative errors and improve clinical outcomes for residents in group home settings.
- Lower acuity long-term care facility resident growth drives core dispensing revenue
- Expansion into new geographic markets increases pharmacy network scale and profitability
- Proprietary technology platform Guardian Compass enhances operational margins through data optimization
- Changes in Medicare and Medicaid reimbursement rates impact net pharmacy margins
- Labor cost inflation for specialized clinical staff affects overall operating expenses
| Net Income: 53.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA 1.91 > 1.0 |
| NWC/Revenue: 5.13% < 20% (prev 1.62%; Δ 3.51% < -1%) |
| CFO/TA 0.21 > 3% & CFO 88.8m > Net Income 53.1m |
| Net Debt (-28.0m) to EBITDA (106.7m): -0.26 < 3 |
| Current Ratio: 1.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.7m) vs 12m ago 1.24% < -2% |
| Gross Margin: 20.93% > 18% (prev 0.20%; Δ 2.07k% > 0.5%) |
| Asset Turnover: 382.7% > 50% (prev 383.9%; Δ -1.25% > 0%) |
| Interest Coverage Ratio: 128.9 > 6 (EBITDA TTM 106.7m / Interest Expense TTM 649k) |
| A: 0.17 (Total Current Assets 235.2m - Total Current Liabilities 160.5m) / Total Assets 426.9m |
| B: 0.19 (Retained Earnings 79.6m / Total Assets 426.9m) |
| C: 0.22 (EBIT TTM 83.7m / Avg Total Assets 380.5m) |
| D: 0.41 (Book Value of Equity 79.7m / Total Liabilities 194.5m) |
| Altman-Z'' = 3.66 = AA |
| DSRI: 1.01 (Receivables 111.7m/97.4m, Revenue 1.46b/1.28b) |
| GMI: 0.95 (GM 20.93% / 19.78%) |
| AQI: 0.89 (AQ_t 0.24 / AQ_t-1 0.27) |
| SGI: 1.14 (Revenue 1.46b / 1.28b) |
| TATA: -0.08 (NI 53.1m - CFO 88.8m) / TA 426.9m) |
| Beneish M = -3.12 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 38.59 with a total of 300,919 shares traded.
Over the past week, the price has changed by +7.73%,
over one month by +1.74%,
over three months by +16.69% and
over the past year by +74.38%.
Guardian Pharmacy Services has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy GRDN.
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 43.2 | 11.9% |
P/E Trailing = 45.8095
P/E Forward = 31.25
P/S = 1.6735
P/B = 11.0307
Revenue TTM = 1.46b USD
EBIT TTM = 83.7m USD
EBITDA TTM = 106.7m USD
Long Term Debt = 29.7m USD (estimated: total debt 36.9m - short term 7.22m)
Short Term Debt = 7.22m USD (from shortTermDebt, last quarter)
Debt = 36.9m USD (from shortLongTermDebtTotal, last quarter) (leases 36.9m already included)
Net Debt = -28.0m USD (calculated: Debt 36.9m - CCE 64.9m)
Enterprise Value = 2.41b USD (2.44b + Debt 36.9m - CCE 64.9m)
Interest Coverage Ratio = 128.9 (Ebit TTM 83.7m / Interest Expense TTM 649k)
EV/FCF = 34.40x (Enterprise Value 2.41b / FCF TTM 70.0m)
FCF Yield = 2.91% (FCF TTM 70.0m / Enterprise Value 2.41b)
FCF Margin = 4.81% (FCF TTM 70.0m / Revenue TTM 1.46b)
Net Margin = 3.64% (Net Income TTM 53.1m / Revenue TTM 1.46b)
Gross Margin = 20.93% ((Revenue TTM 1.46b - Cost of Revenue TTM 1.15b) / Revenue TTM)
Gross Margin QoQ = 22.67% (prev 21.50%)
Tobins Q-Ratio = 5.64 (Enterprise Value 2.41b / Total Assets 426.9m)
Interest Expense / Debt = 1.76% (Interest Expense 649k / Debt 36.9m)
Taxrate = 25.96% (4.75m / 18.3m)
NOPAT = 62.0m (EBIT 83.7m * (1 - 25.96%))
Current Ratio = 1.46 (Total Current Assets 235.2m / Total Current Liabilities 160.5m)
Debt / Equity = 0.17 (Debt 36.9m / totalStockholderEquity, last quarter 220.9m)
Debt / EBITDA = -0.26 (Net Debt -28.0m / EBITDA 106.7m)
Debt / FCF = -0.40 (Net Debt -28.0m / FCF TTM 70.0m)
Total Stockholder Equity = 195.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.95% (Net Income 53.1m / Total Assets 426.9m)
RoE = 27.21% (Net Income TTM 53.1m / Total Stockholder Equity 195.0m)
RoCE = 37.25% (EBIT 83.7m / Capital Employed (Equity 195.0m + L.T.Debt 29.7m))
RoIC = 25.94% (NOPAT 62.0m / Invested Capital 238.9m)
WACC = 7.60% (E(2.44b)/V(2.47b) * Re(7.70%) + D(36.9m)/V(2.47b) * Rd(1.76%) * (1-Tc(0.26)))
Discount Rate = 7.70% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 84.52 | Cagr: 3.25%
[DCF] Terminal Value 77.97% ; FCFF base≈61.4m ; Y1≈70.3m ; Y5≈103.5m
[DCF] Fair Price = 31.85 (EV 1.56b - Net Debt -28.0m = Equity 1.59b / Shares 49.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.06 | # QB: 0
Revenue Correlation: 99.72 | Revenue CAGR: 16.99% | SUE: 1.05 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.26 | Chg30d=-0.11% | Revisions=+0% | Analysts=6
EPS next Quarter (2026-09-30): EPS=0.30 | Chg30d=-0.10% | Revisions=-25% | Analysts=6
EPS current Year (2026-12-31): EPS=1.26 | Chg30d=+2.94% | Revisions=+43% | GrowthEPS=+17.8% | GrowthRev=-2.4%
EPS next Year (2027-12-31): EPS=1.36 | Chg30d=+0.32% | Revisions=+25% | GrowthEPS=+7.8% | GrowthRev=+7.7%
[Analyst] Revisions Ratio: +43%